MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2021 Earnings Conference Call February 28, 2022 5:00 PM ET Company Participants Jack Howarth - Senior Vice President, Investor Relations Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Rohit Kashyap - Executive Vice President and Chief Commercial Officer Robert Stein - Executive Vice President, Research and Development Conference Call Participants Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Call Start: 08:30 January 1, 0000 9:32 AM ET MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2021 Earnings Conference Call November 3, 2021 08:30 ET Company Participants Alexandra Haden - General Counsel & Secretary Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Rohit Kashyap - Executive Vice President & Chief Commercial Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Small Cap Research Eiad Asba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants Jack Howarth - SVP of IR Tim Wright - CEO Pete Carlson - CFO Robert Stein - EVP of R&D Rohit Kashyap - EVP and CCO Conference Call Participants Carl Byrnes - Northland Securities John Vandermosten - Zacks SCR Sean Lee - H.C. Wainwright Eiad Asbahi - Prescience Point Capital Operator Ladies and gentlemen, thank you for standing by. And welcome to MiMedx Second Quarter 2021 Operating and Financial ...

MIMEDX GROUP, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 Securities registered pursuant to Section 12(b) of the Act: | | | Name o ...

Financial Data and Key Metrics Changes - MiMedx reported a 4% growth in adjusted net sales for Q1 2021, driven by the Wound Care business, with adjusted net sales reaching $59.7 million, an increase of 4.2% from the previous year [11][45] - Net sales for Q1 2021 were $60.0 million, compared to $61.7 million for the same period in 2020, reflecting a decline due to changes in revenue recognition methodology [44][45] - Gross margin improved slightly to 83.9% in Q1 2021 from 83.8% in Q1 2020 [46] - Net loss increased to $8.4 million in Q1 2021 from a net loss of $4.8 million in Q1 2020 [50] Business Line Data and Key Metrics Changes - The Wound Care business was a significant contributor to the growth, particularly due to the recently launched EpiCord Expandable product [11][12] - Selling, general and administrative expenses decreased by 3.8% to $45.2 million, attributed to lower travel expenses due to COVID-19 restrictions [46] - Research and development expenses increased to $4.3 million in Q1 2021 from $2.8 million in the same period last year, reflecting planned investments in clinical research [47] Market Data and Key Metrics Changes - The company noted that sales of marginized and particulate products represented approximately 14% of net sales for the three months ended March 31, 2021 [53] - The FDA's end of enforcement discretion is expected to impact sales, with the company anticipating adjusted net sales for 2021 to be consistent with the previous year [54] Company Strategy and Development Direction - MiMedx is focused on pipeline acceleration, expanding patient access to wound care products, and advancing its innovative pipeline of musculoskeletal therapies [58] - The company is exploring inorganic growth opportunities but emphasizes a focus on organic growth at this time [41][42] - The addition of Dirk Stevens as Senior Vice President of Quality Assurance and Regulatory Affairs is aimed at enhancing quality standards and regulatory compliance [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to achieve above-market growth rates despite the challenges posed by the end of enforcement discretion [71] - The company is committed to ensuring patient access to its products and is working with the FDA on expanded access under a cost recovery model [82] - Management highlighted the importance of ongoing dialogue with the FDA and the positive feedback received regarding their compliance efforts [75][86] Other Important Information - The company has completed the final patient visits for its Phase III studies on AmnioFix injectable for plantar fasciitis and Achilles tendonitis, with top-line results expected in the summer [19][22] - MiMedx is planning to file its first Biologics License Application (BLA) in the first half of 2022 for plantar fasciitis [27][75] Q&A Session Summary Question: Clarification on Year-over-Year Sales Decline - The decline in year-over-year sales was due to a change in revenue recognition methodology, not lost contracts [66][68] Question: Mitigation Strategies for Sales Loss - The company is focusing on expanding its sheet products and deploying its medical education team to communicate value propositions effectively [70][71] Question: FDA Approval Requirements for AmnioFix Injectable - Key steps include completing the analysis of the Phase III trial, meeting with the FDA, and ensuring the manufacturing facility meets GMP standards [73][75] Question: Impact of Enforcement Discretion Ending - Sales will continue until May 31, 2021, after which normal sales will stop without an approved BLA [79][81] Question: Market Size for Chronic Cutaneous Ulcers - The market for chronic cutaneous ulcers is expected to be significant, potentially larger than existing markets for diabetic foot ulcers and venous leg ulcers [93][96]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-27925 ...

| --- | --- | --- | |------------------------------------------------------------|-------------------------------|-------| | | | | | | | | | MiMedx | | | | ADVANCED PLACENTAL SCIENCE March 9-10, 2021 | INNOVATING TREATMENTS THROUGH | | | 2021 H.C. Wainwright & Co. Global Life Sciences Conference | | | IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Actual results may differ materially. Investors are cautioned against placing undue reliance on these statements, All state ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2020 Earnings Conference Call March 8, 2021 9:30 AM ET Company Participants Jack Howarth - VP of IR and Corporate Communications Tim Wright - CEO Pete Carlson - CFO Robert Stein - EVP, Research & Development Rohit Kashyap - EVP and Chief Commercial Officer Conference Call Participants Sean Kang - H.C. Wainwright John Vandermosten - SIC Zacks Eiad Asbahi - Prescience Point Operator Ladies and gentlemen, thank you for standing by, and welcome to the MiMedx Fourth Quarter 20 ...